TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
The Department of Justice says Michigan physician Jonathan Decker was convicted of peddling more than 2 million stimulant pills through the Done ADHD telehealth platform. Separately, Click Therapeutics said the FDA cleared Motivista as an adjunctive digital treatment for negative symptoms of schizophrenia in outpatient care. The source report also notes growing attention to AI-related anxiety in therapy, but provides few details about that trend.
A Michigan physician, Jonathan Decker, was convicted in a case involving more than 2 million stimulant pills, according to the U.S. Department of Justice, while the FDA cleared a separate digital therapeutic for some schizophrenia symptoms, Click Therapeutics said. The developments, reported by MedPage Today on October 7, 2026, concern both oversight of online stimulant prescribing and the expanding role of digital products in psychiatric care.
The Department of Justice said Decker was convicted of peddling more than 2 million stimulant pills, including amphetamine-dextroamphetamine salts, commonly sold under the brand name Adderall, on the Done ADHD telehealth platform. The source report does not specify the charges, trial court, verdict date, sentence, or whether other defendants were involved. It also does not include a statement from Decker or his representatives.
In a separate development, Click Therapeutics said the FDA cleared its prescription digital therapeutic, Motivista, as an adjunctive treatment for negative symptoms of schizophrenia in outpatient care. That description indicates the product is intended to be used alongside other care, rather than as a standalone replacement. The report does not provide the clearance date, product instructions, clinical results, or details of the patient group covered.
The roundup also cited a New York Times report that anxiety about artificial intelligence is becoming a prominent topic in therapy sessions. It offered no survey figures or clinical findings to quantify how often this comes up or how it affects patients. Other items in the report included the FDA seeking public feedback on ibogaine development and a national survey finding stronger public support for the civil rights of people with severe physical disabilities than for people with mental illness or substance use disorder.
Stimulant Oversight and Digital Care
The conviction places attention on how controlled stimulants are prescribed through telehealth services, where patients and clinicians may interact remotely. The DOJ’s account identifies a large number of pills and a named platform, but the short report does not establish what evidence was presented at trial, how prescribing decisions were made, or what safeguards were in place. Those details matter to understanding the case and its implications for other online providers.
Motivista’s clearance marks a separate development in the use of prescription digital therapeutics for psychiatric care. A digital product cleared as an adjunct may add another option for outpatient treatment, but clearance alone does not show how widely it will be prescribed, how patients will access it, or what outcomes it produces in routine care. The source report provides no efficacy or safety data, so the scope of its potential impact cannot be assessed from this account.
The mention of AI-related anxiety points to a subject entering therapy conversations, but the available reporting does not establish whether the concern is rising across the population or changing treatment needs. The items are linked by their relevance to mental health care, not by evidence of a single underlying trend.
As an affiliate, we earn on qualifying purchases.
Three Developments in Psychiatry
MedPage Today published the roundup on October 7, 2026, drawing on announcements and reporting from several organizations and publications. The pill case was attributed to the Department of Justice; the Motivista clearance was attributed to Click Therapeutics. The AI-anxiety item was attributed to The New York Times, while other points came from studies or reports identified in the roundup.
The roundup also said the FDA is soliciting public feedback on ibogaine drug development to help shape future early-phase clinical trials. It cited a JAMA Health Forum national survey on differences in public support for civil rights, and a study in Psychological Medicine associating psilocybin use among adults with depression with a higher perceived unmet treatment need. These are distinct findings and should not be read as proof of causation or as evidence about the two principal developments.
Other cited items included Vanda Pharmaceuticals’ report that tasimelteon met a primary endpoint in a phase III trial for delayed sleep-wake phase disorder, and a study indicating that some Medicaid-enrolled young people with opioid use disorder started treatment while far fewer received sustained pharmacotherapy. The brief roundup does not provide enough detail to evaluate those findings independently.
“The FDA cleared the prescription digital therapeutic Motivista as an adjunctive treatment for negative symptoms of schizophrenia in outpatient care.”
— Click Therapeutics, as summarized by MedPage Today
As an affiliate, we earn on qualifying purchases.
Court and Clearance Details Missing
The report does not identify the specific convictions or charges in Decker’s case, the court, the date of the verdict, or any sentence. It is also unclear whether an appeal is planned, whether the DOJ alleged particular prescribing practices, or what role other people at Done ADHD may have had. No response from Decker or the platform appears in the source material.
For Motivista, the source does not state the clearance date, the evidence reviewed by the FDA, or the product’s labeled use and access conditions. It does not report trial results, risks, or how the treatment will be incorporated into outpatient care. The AI-anxiety report likewise gives no data on prevalence, causes, or clinical consequences. Those points remain unconfirmed in the available account.
prescription digital therapeutics for mental health
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Further Records and Product Details
Further information about Decker’s case would be expected from court records or a fuller DOJ announcement, including the charges, sentence, and any post-verdict proceedings. The source material does not give a schedule for those developments or say whether the case is still active beyond the reported conviction.
Click Therapeutics or the FDA may provide more detail on Motivista’s clearance, including its intended use, clinical evidence, and availability. The FDA’s separate request for public feedback on ibogaine development is intended to inform future early-phase trials, but the report gives no submission deadline or trial timeline. No next milestone is specified for the reporting on AI anxiety in therapy.
As an affiliate, we earn on qualifying purchases.
Key Questions
What was Jonathan Decker convicted of?
The Department of Justice, as summarized by MedPage Today, said the Michigan physician was convicted of peddling more than 2 million stimulant pills, including amphetamine-dextroamphetamine salts, through the Done ADHD telehealth platform. The source does not list the specific charges or sentence.
What is Motivista?
Motivista is a prescription digital therapeutic that Click Therapeutics said the FDA cleared as an adjunctive treatment for negative symptoms of schizophrenia in outpatient care. The report does not provide product-use instructions or clinical results.
Does the report show that AI anxiety is increasing?
No. It says anxiety about AI is becoming a prominent topic in therapy sessions, citing The New York Times, but gives no prevalence figures or trend data to measure a rise.
What details are still unknown about the conviction?
The roundup does not state the charges, court, verdict date, sentence, or appeal status. It also does not include comment from Decker or his representatives.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
